KARV Y ||| EEE Financials- Consolidated Exhibit 15: Profit and Loss Statement YE Mar (Rs ma) NetRevenaes % Growth Rew Material Staff (ther Expenses Total Expenditures EBITDA % Growth [EBITDA Margins (%) (Other Income Interest Depreciation Profit Before Tax Provision for tax Effective tax rate (%) Reported PAT % Growth Adjusted Net Profit % Growth ‘Source: Company, Karvy Institutional Research Exhibit 16: Balance Sheet YE Mar Equity Share Capital Reserves & surplus Shareholders’ funds Minorities interests Total Debt Capital Employed Net fixed assets ash & Cash Eq. Net Other current assets Investments Net Deferred tax Assets Total Assets Source: Company, KarayTnsitational Research FYit 6174 33 3.203 813 1432 5487 nm 1) na 2 238 27 a4 19 34 46 51) 536 @o rn a 6230 6am 690 7,006 2,607 2,809 1,199 607 (216) 7,006 Fyiz 9,130 “79 5,030 1136 2122 8288 a 158 92. a 440 25 890 11 190 732 635 589 97, Fy a 5897 397 66 5407 1481 9,383 1,381 903 16) 1431 October 18,2012 Jyothy Laboratories FYE TR a8 499 7377 1a 3.239 11,828 1858 1208 136 5a 268 1,198 205 199 953 257 953 619 FYME T6561 210 8784 1A13 3.986 14,188 2378 280 a 787 280 199 Last 505 14a 305 FYE ra 6.166 6,328 181 4633 ast 10,381 758 2s ast) mast FYISE 161 oan 6503 288 sass 10938 10316 “7 96 15 ast) 10934 3KARVYiIIl STOCK BROKING Exhibit 17: Cash Flow Statement YPE Mar (Rs mn) FY PBT a2 Depreciation 130 Tax 25) (Change in Wkg Cap. (683) CF from Operations 65) Capex G48) Investments e172) CF from Investing, 2.330) (Change in Equity 2.284 (Change in Debt 360 Dividends & others 28) (CF from Financing 2484 in Cash a) ‘Source: Company, Karvy Institutional Research Exhibit 18: Key Ratios YE Mar FY Raw Material Cost/Sales %) 39 Manpower CostiSales (%) 132 Operating & Other CostSales (%) 232 Revenue Growth (1%) EBITDA Margins (%) Net Income Margins (%) ROCE (%) ROE (%) ‘Source: Company, Karvy Institutional Research Exhibit 19: Valuation Parameters YIE Mar Fi EPS (Rs) eB PIE (s) 309 BY (Rs) 391 PIBY (x) 43 EV/EBITDA (x) 340 Fixed assets tumover ratio (x) 28 Net Debt Equity () 03) Evisales 40 ‘Source: Company, Karvy Institutional Research (646) 4.338 2 432 ay FyI2 3 14 22 “79 Fyiz 3 Si 380 385 25 os. 35 October 18,2012 Jyothy Laboratories (500) (943) 1950) 28) FYE 59 88 237 499 136 70 162. 153 FYE L787 275 (280) 570 2,886 (28) (28) (600) (azz (2,355) 30 FYE 50 85 4A no 144 87 as 2, FYME 39 191 392 43 132 5a 0s 1 1,698) 2.675) 3) FYISE a 84 239 198 143 94 260 288 FYISE 116 146 403 42 109 61 05. 16 96